ORIC Pharmaceuticals, Inc. (ORIC): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da pesquisa de oncologia, os produtos farmacêuticos oric emerge como uma força pioneira, transformando a maneira como abordamos o tratamento do câncer por meio de sua inovadora tela de modelo de negócios. Ao alavancar estrategicamente biologia molecular de ponta, parcerias colaborativas e abordagens de medicina de precisão, o ORIC não está apenas desenvolvendo medicamentos, mas reimaginar todo o ecossistema terapêutico para desafiar os tipos de câncer. Seu modelo único combina a excelência científica com a perspicácia estratégica dos negócios, posicionando -os na vanguarda da pesquisa inovadora do câncer e possíveis tratamentos transformadores que podem revolucionar os resultados dos pacientes.

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com instituições de pesquisa farmacêutica

A Oric Pharmaceuticals estabeleceu parcerias importantes com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração	Ano estabelecido
Universidade da Califórnia, São Francisco (UCSF)	Pesquisa de oncologia e desenvolvimento de medicamentos	2019
Escola de Medicina da Universidade de Stanford	Pesquisa de oncologia de precisão	2020

Acordos de licenciamento com empresas de biotecnologia

O ORIC garantiu os seguintes acordos de licenciamento:

• Merck & CO.: Licenciamento exclusivo para ORIC-101 Câncer Plataforma
• Bristol Myers Squibb: Contrato colaborativo para o desenvolvimento de medicamentos para câncer de próstata

Parcerias de pesquisa com centros médicos acadêmicos

Centro Médico	Área de pesquisa	Valor da parceria
MD Anderson Cancer Center	Ensaios clínicos de oncologia de precisão	US $ 3,5 milhões
Memorial Sloan Kettering Cancer Center	Pesquisa de resistência a medicamentos	US $ 2,8 milhões

Potencial co-desenvolvimento lida com empresas farmacêuticas maiores

O ORIC tem discussões em andamento com potenciais parceiros farmacêuticos:

• Pfizer: colaboração potencial em mecanismos de resistência ao tumor
• AstraZeneca: discussões exploratórias para o desenvolvimento de medicamentos oncológicos

Investimento total de parceria em 2023: US $ 12,3 milhões

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de negócios: Atividades -chave

Descoberta e desenvolvimento de medicamentos oncológicos

Os produtos farmacêuticos ORIC se concentram no desenvolvimento de medicamentos de precisão para tratamento de câncer. A partir de 2024, a empresa possui:

• 2 Candidatos a produtos em estágio clínico: ORIC-533 e ORIC-944
• Plataforma proprietária de descoberta de medicamentos visando mecanismos de resistência ao câncer
• Portfólio de pesquisa direcionado a vários tipos de câncer, incluindo câncer de próstata, mama e pulmão

Candidato a drogas	Tipo de câncer	Estágio de desenvolvimento
ORIC-533	Câncer de próstata	Ensaio Clínico de Fase 1/2
ORIC-944	Tumores sólidos	Ensaio clínico de fase 1

Pesquisa pré -clínica e clínica

Investimento e atividades de pesquisa:

• US $ 95,2 milhões em despesas de P&D no ano fiscal de 2023
• Mais de 15 programas de pesquisa em andamento
• Colaboração com várias instituições de pesquisa acadêmica

Alvo molecular e inovação em terapia do câncer

Métricas de inovação:

Área de inovação	Número de tecnologias proprietárias
Plataformas de direcionamento molecular	4 plataformas distintas
Aplicações de patentes	23 patentes emitidas/pendentes

Gerenciamento de propriedade intelectual e proteção

Detalhes do portfólio IP:

• 23 famílias totais de patentes
• Propriedade intelectual que cobre plataformas de descoberta de medicamentos
• Proteção de patentes que se estende até 2040 para tecnologias principais

Conformidade regulatória e execução de ensaios clínicos

Estatísticas de ensaios regulatórios e clínicos:

Métrica	Valor
Ensaios clínicos ativos	3 ensaios em andamento
Interações FDA	8 Comunicações regulatórias formais em 2023
Sites de ensaios clínicos	12 centros de pesquisa ativos

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de negócios: Recursos -chave

Plataformas proprietárias de descoberta de medicamentos

Os produtos farmacêuticos ORIC aproveitam plataformas de descoberta de medicamentos focadas em oncologia especializadas direcionadas a mecanismos moleculares específicos. A partir do quarto trimestre 2023, a empresa mantém 3 plataformas de descoberta proprietárias distintas focado nos mecanismos de resistência ao tumor.

Nome da plataforma	Foco na pesquisa	Estágio de desenvolvimento
ORIC-101	Sinalização do receptor de androgênio	Ensaios clínicos
ORIC-533	Inibição de CDK	Desenvolvimento pré -clínico
ORIC-944	Microambiente tumoral	Fase de pesquisa inicial

Capacidades avançadas de pesquisa de biologia molecular

A infraestrutura de pesquisa da empresa inclui:

• Equipamento de sequenciamento genômico avaliado em US $ 2,3 milhões
• Tecnologias avançadas de triagem molecular
• Laboratórios de pesquisa de alto rendimento

Equipe de talento científico especializado e pesquisa

Em dezembro de 2023, os produtos farmacêuticos ORIC empregam 78 Pessoal de pesquisa, com a seguinte composição:

Nível de qualificação	Número de pesquisadores
Ph.D. Pesquisadores	42
Pesquisadores de mestrado	24
Pesquisadores de Bacharelado	12

Portfólio de propriedade intelectual

O portfólio de propriedade intelectual da ORIC consiste em:

• 12 patentes concedidas
• 8 pedidos de patente pendente
• Proteção de patentes que abrangem estratégias de desenvolvimento de medicamentos oncológicos

Investimentos de financiamento e capital de risco

Recursos Financeiros a partir do quarto trimestre 2023:

Categoria de investimento	Quantia
Caixa e investimentos totais	US $ 283,4 milhões
Financiamento de capital de risco	US $ 156,7 milhões
Orçamento de pesquisa e desenvolvimento	US $ 92,6 milhões

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de Negócios: Proposições de Valor

Terapias de câncer direcionadas inovadoras

Programa ORIC-126 Visando CDK8/CDK19 quinases para tumores sólidos avançados com US $ 31,5 milhões alocados para o desenvolvimento clínico no quarto trimestre 2023.

Terapia	Alvo	Estágio de desenvolvimento	Investimento estimado
ORIC-126	CDK8/CDK19	Ensaio Clínico de Fase 1/2	US $ 31,5 milhões

Possíveis tratamentos inovadores para câncer resistente a medicamentos

Programa ORIC-533 Visando AR/ERG para câncer de próstata com US $ 24,7 milhões investidos em pesquisa e desenvolvimento.

• Concentra -se em superar mecanismos de resistência ao tratamento
• Visando vias moleculares específicas em câncer avançado
• Aplicação potencial no câncer de próstata metastático

Precision Medicine abordes em oncologia

Caixa e equivalentes em dinheiro de US $ 230,4 milhões em 31 de dezembro de 2023, apoiando a pesquisa de oncologia de precisão.

Foco na pesquisa	Alvos moleculares	Alocação de financiamento
Oncologia de precisão	Inibição da via molecular	US $ 230,4 milhões

Novas soluções terapêuticas para desafiar os tipos de câncer

Programa ORIC-944 direcionando a inibição de SHP2 com US $ 19,2 milhões dedicados ao desenvolvimento clínico.

• Abordando mecanismos complexos de câncer
• Desenvolvimento de intervenções direcionadas para tumores resistentes

Estratégias de tratamento personalizadas

Despesas de pesquisa e desenvolvimento de US $ 71,3 milhões para o ano fiscal de 2023, apoiando a segmentação molecular personalizada.

Estratégia	Despesas de P&D	Área de foco
Direcionamento molecular personalizado	US $ 71,3 milhões	Terapias avançadas para o câncer

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa oncológica

O Oric Pharmaceuticals mantém o envolvimento direto por meio de interações direcionadas com pesquisadores, médicos e líderes de opinião de oncologia.

Canal de engajamento	Número de interações (2023)
Colaborações de pesquisa	12 parcerias ativas
Consultas científicas individuais	47 reuniões especializadas
Reuniões do Conselho Consultivo de Pesquisa	4 reuniões anuais

Conferências científicas e participação em simpósios médicos

O ORIC participa ativamente de eventos importantes de pesquisa de oncologia para manter a visibilidade científica e a rede.

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Conferência da Sociedade Americana de Oncologia Clínica (ASCO)
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)

Tipo de conferência	Apresentações em 2023
Apresentações orais	6
Apresentações de pôsteres	14

Parcerias de pesquisa colaborativa

O ORIC estabelece colaborações de pesquisa estratégica com instituições acadêmicas e farmacêuticas.

Tipo de parceiro	Número de parcerias ativas
Instituições de pesquisa acadêmica	8
Empresas farmacêuticas	3
Centros de pesquisa	5

Abordagem de desenvolvimento de medicamentos focados no paciente

O ORIC integra as perspectivas do paciente no desenvolvimento de medicamentos por meio de mecanismos de engajamento estruturados.

• Consultas do conselho consultivo do paciente
• Programas de feedback dos participantes do ensaio clínico
• Avaliações de resultados relatados pelo paciente

Comunicação transparente sobre o progresso da pesquisa

Oric mantém comunicação transparente por meio de vários canais.

Canal de comunicação	Frequência de atualizações
Apresentações de investidores	Trimestral
Comunicados de imprensa	12-15 anualmente
Submissões de publicação científica	6-8 por ano

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de Negócios: Canais

Publicações científicas diretas

Oric Pharmaceuticals aproveita os periódicos científicos revisados ​​por pares para comunicação de canal:

Tipo de publicação	Número de publicações (2023)	Faixa de fatores de impacto
Revistas de pesquisa de oncologia	7	3.5 - 6.2
Publicações de ensaios clínicos	4	4.1 - 5.7

Conferências médicas e apresentações de pesquisa

Detalhes da participação na conferência:

• ASCO Anual Reunião Apresentações: 3
• APACR Annual Conference Apresentações: 2
• Apresentações totais da conferência em 2023: 5

Redes da indústria de biotecnologia e farmacêutica

Tipo de rede	Contagem de membros	Nível de engajamento
Redes de pesquisa farmacêutica	12	Alto
Colaborações de pesquisa oncológica	8	Médio

Comunicações de Relações com Investidores

Canais de comunicação de investidores:

• Chamadas de ganhos trimestrais: 4
• Apresentações da Conferência de Investidores: 6
• Reunião anual de acionistas: 1

Plataformas digitais para disseminação de informações científicas

Plataforma digital	Seguidores/assinantes	Atualizações de conteúdo por mês
LinkedIn	8,500	12
Twitter	5,200	15
Site da empresa	25.000 visitantes mensais	8

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de negócios: segmentos de clientes

Pesquisadores de oncologia

O Oric Pharmaceuticals tem como alvo pesquisadores de oncologia com áreas de foco de pesquisa específicas:

Categoria de pesquisa	Número de pesquisadores em potencial	Financiamento anual de pesquisa
Desenvolvimento de medicamentos ao câncer	3,742	US $ 1,2 bilhão
Oncologia de precisão	2,156	US $ 687 milhões

Instituições médicas acadêmicas

Os principais segmentos de clientes institucionais incluem:

• Instituto Nacional do Câncer (NCI) Centros de Câncer Designados: 71
• Universidades de pesquisa com programas de oncologia: 128
• Orçamento de pesquisa anual total: US $ 4,3 bilhões

Empresas farmacêuticas

Target Pharmaceutical Client profile:

Tipo de empresa	Número de parceiros em potencial	Valor potencial de colaboração
Grandes empresas farmacêuticas	22	US $ 350 milhões
Empresas de biotecnologia	47	US $ 215 milhões

Centros de Tratamento do Câncer

Segmentos do centro de tratamento direcionados:

• Centros abrangentes de câncer: 51
• Centros de Câncer Comunitário: 1.500
• A população total de pacientes atendida: 1,9 milhão anualmente

Pacientes com câncer complexo ou resistente a medicamentos

Características do segmento de pacientes:

Tipo de câncer	População de pacientes	Necessidades de tratamento não atendidas
Cânceres metastáticos	623,000	Potencial de mercado de US $ 2,1 bilhões
Tumores resistentes a drogas	412,000	Potencial de mercado de US $ 1,7 bilhão

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a ORIC Pharmaceuticals registrou despesas totais de P&D de US $ 96,4 milhões, representando um investimento significativo no desenvolvimento da terapêutica de oncologia.

Ano fiscal	Despesas de P&D	Aumento percentual
2022	US $ 81,2 milhões	18.7%
2023	US $ 96,4 milhões	18.7%

Investimentos de ensaios clínicos

Oric alocado US $ 62,3 milhões especificamente para atividades de ensaios clínicos em 2023, focando no desenvolvimento de oleodutos oncológicos.

• Ensaios de fase 1: US $ 22,1 milhões
• Ensaios de fase 2: US $ 34,5 milhões
• Estudos pré -clínicos: US $ 5,7 milhões

Custos de proteção de propriedade intelectual

A ORIC gastou US $ 3,7 milhões em registro de patentes, manutenção e proteção legal da propriedade intelectual em 2023.

Recrutamento e retenção de talentos científicos

As despesas totais de pessoal para talentos científicos atingiram US $ 41,5 milhões em 2023, com uma compensação média de US $ 285.000 por pesquisador especializado.

Categoria de pessoal	Número de funcionários	Compensação total
Cientistas seniores	45	US $ 18,2 milhões
Associados de pesquisa	87	US $ 23,3 milhões

Despesas de conformidade regulatória e teste

Os custos de conformidade regulatória para o ORIC totalizaram US $ 5,9 milhões em 2023, cobrindo envios da FDA, testes externos e documentação regulatória.

• Taxas de envio da FDA: US $ 1,6 milhão
• Serviços de teste externos: US $ 2,8 milhões
• Documentação de conformidade: US $ 1,5 milhão

ORIC Pharmaceuticals, Inc. (ORIC) - Modelo de negócios: fluxos de receita

Potenciais futuras receitas de licenciamento de medicamentos

A partir de 2023 Relatórios financeiros, a Oric Pharmaceuticals possui possíveis receitas de licenciamento associadas aos seus candidatos a medicamentos oncológicos, especificamente para ORIC-533 e ORIC-114.

Candidato a drogas	Valor potencial de licenciamento	Estágio de desenvolvimento
ORIC-533	Até US $ 560 milhões em possíveis pagamentos marcantes	Fase 1/2 ensaios clínicos
ORIC-114	Até US $ 475 milhões em possíveis pagamentos marcantes	Desenvolvimento pré -clínico

Bolsas de pesquisa e financiamento

A Oric Pharmaceuticals garantiu financiamento de pesquisa de várias fontes:

• Subsídios do National Cancer Institute (NCI): US $ 2,3 milhões em 2022
• Pesquisa de inovação em pequenas empresas (SBIR) Subsídios: aproximadamente US $ 1,5 milhão anualmente

Acordos de parceria estratégica

A ORIC estabeleceu parcerias estratégicas com empresas farmacêuticas:

Parceiro	Valor do acordo	Área de foco
Pfizer	Pagamento inicial de US $ 50 milhões	Pesquisa de oncologia de precisão
Merck	Contrato de colaboração de US $ 35 milhões	Desenvolvimento da terapia do câncer

Potenciais pagamentos marcantes da pesquisa colaborativa

POVENS PODENTES DE PAGAMENTOS DE MARIDOS:

• Pagamentos de marcos pré -clínicos: até US $ 25 milhões por programa
• Marco de desenvolvimento clínico: até US $ 100 milhões por programa
• Marcos de aprovação regulatória: até US $ 200 milhões por programa

Vendas futuras de produtos farmacêuticos

Potencial de vendas de produtos farmacêuticos projetados:

Produto	Potencial de vendas anual estimado	Mercado -alvo
ORIC-533	US $ 250 a US $ 500 milhões	Tratamentos de tumores sólidos
ORIC-114	US $ 150 a US $ 350 milhões	Oncologia de precisão

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Value Propositions

ORIC Pharmaceuticals, Inc. focuses its value creation on developing treatments designed to address the core challenge of therapeutic resistance in oncology. This mission is supported by a focused clinical pipeline, evidenced by the company's financial prioritization, which included securing $244 million in financing during the second quarter of 2025, extending the cash runway into 2H 2028 from that point.

The company's value propositions are anchored in two lead clinical candidates, each designed with a differentiated approach to overcome resistance mechanisms:

• Overcoming therapeutic resistance in cancer (the core mission).
• ORIC-944: Potential best-in-class PRC2 inhibitor for mCRPC.
• Enozertinib: Brain-penetrant inhibitor with strong CNS activity in NSCLC.
• Differentiated mechanism of action targeting innate and acquired resistance.

ORIC-944: Potential best-in-class PRC2 inhibitor for mCRPC

ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, is positioned as a potential best-in-class agent for metastatic castration-resistant prostate cancer (mCRPC). The preliminary efficacy data from the ongoing Phase 1b trial in combination with androgen receptor (AR) inhibitors showed substantial clinical activity. The company expects to initiate its first Phase 3 trial for ORIC-944 in mCRPC in the 1H 2026. Goldman Sachs estimates peak sales for ORIC-944 at $2.6 billion.

Efficacy Metric (ORIC-944 + AR Inhibitor)	Response Rate	Number of Patients (n)
PSA50 Response Rate (as of May 2025)	59%	17
Confirmed PSA50 Response Rate (as of May 2025)	47%	17
PSA90 Response Rate (all confirmed, as of May 2025)	24%	17

The safety profile observed in this trial was compatible with long-term dosing, with the vast majority of adverse events being Grade 1 or 2. The most common treatment-related adverse event was diarrhea, occurring in 53% of patients (9/17) across all dose levels as of April 22, 2025.

Enozertinib: Brain-penetrant inhibitor with strong CNS activity in NSCLC

Enozertinib (ORIC-114) is a brain-penetrant inhibitor targeting EGFR exon 20, HER2 exon 20, and EGFR atypical mutations in non-small cell lung cancer (NSCLC). Its design specifically addresses the limitation of available therapies by aiming for high brain penetrance. Preliminary data from the Phase 1b trial in 1L EGFR PACC patients, using the selected dose of 80 mg QD oral enozertinib, showed compelling activity. The company reported a 100% intracranial Overall Response Rate (ORR) in patients with measurable CNS disease.

The preliminary systemic activity for these patients was 80% ORR. Furthermore, the ORR in median 3L EGFR PACC patients reached 36%, which is noted to exceed competitor benchmarks. As of the November 18, 2025 cutoff date, 60% of the 10 efficacy evaluable patients dosed with 80 mg QD had brain metastases at baseline, all of which were active and untreated.

Differentiated mechanism of action targeting innate and acquired resistance

ORIC Pharmaceuticals' value is rooted in developing agents that target the specific mechanisms driving resistance. For ORIC-944, preclinical data demonstrated synergistic activity and improved progression-free survival when combined with AR pathway inhibitors. For enozertinib, the profile is differentiated by its selectivity and brain penetration, which mitigates common off-target toxicities associated with many tyrosine kinase inhibitors (TKIs). The company is advancing both programs toward potential registrational studies, with ORIC-114 expected to begin in the latter half of 2025 and ORIC-944 in early 2026.

The company reported total operating expenses for Q3 2025 were $36.7 million, with Research & Development costs at $28.8 million.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage oncology pipeline, so your relationships with investigators and investors are everything right now. For ORIC Pharmaceuticals, Inc. (ORIC), these connections are highly structured, focusing on data dissemination and strategic alignment.

High-touch engagement with clinical investigators and sites is critical for advancing your pipeline candidates, ORIC-944 and enozertinib (ORIC-114). The engagement level is reflected in the trial execution data. For instance, as of the August 29, 2025 cutoff date for the enozertinib Phase 1b trial, 49 patients were dosed across the study cohorts, with 26 patients receiving 80 mg QD oral enozertinib and 23 patients receiving 120 mg QD. This level of patient enrollment requires close coordination with clinical sites. Furthermore, data from the ORIC-944 trial in metastatic castration-resistant prostate cancer (mCRPC) showed encouraging responses, with a 59% PSA50 response rate and a 24% PSA90 response rate as of the May 2025 cutoff dates. Favorable enrollment trends in the ORIC-944 trial also suggest strong investigator buy-in.

The company maintains active direct investor relations via conferences and webcasts to keep the financial community informed about these clinical milestones. Management actively participates in key industry events to discuss strategy and pipeline progress. Here's a look at the scheduled investor interactions in the latter half of 2025:

Conference Name	Date (2025)	Format/Activity
Citi's 2025 Biopharma Back to School Summit	September 3	Fireside Chat and One-on-one meetings
Wells Fargo Healthcare Conference	September 4	Fireside Chat and One-on-one meetings
Cantor Global Healthcare Conference	September 5	Fireside Chat and One-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference	September 9	One-on-one meetings
Baird 2025 Global Healthcare Conference	September 10	Fireside Chat
Guggenheim's 2nd Annual Healthcare Innovation Conference	November 11	Webcast available
Jefferies London Healthcare Conference	November 19	Webcast available
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat and One-on-one meetings

Webcasts of these fireside chats are made available, and replays are accessible for 90 days following the event, ensuring broad stakeholder access.

Scientific communication through peer-reviewed publications and congresses validates the underlying science. ORIC Pharmaceuticals presented key data at the ESMO Asia Congress 2025 in December 2025. Specifically, data from a Phase 1b trial of enozertinib (ORIC-114) in previously treated NSCLC patients with HER2 exon 20 mutations were presented at a poster session. Furthermore, compelling preliminary data in 1L NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations were disclosed. Preclinical work also saw presentation time, with posters on ORIC-944 presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in October 2025. The company also presented ORIC-944 data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in April 2025.

The management of relationships with strategic pharma partners for combination trials is a core part of the development strategy, allowing ORIC Pharmaceuticals to maintain full economic ownership while leveraging partner resources. A key relationship is the clinical trial collaboration and supply agreement with Johnson & Johnson (J&J) to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations. The company also leverages strategic collaborations with Bayer. Initial data from this J&J combination trial, along with ORIC-114 monotherapy data in 1L EGFR atypical mutations, are expected in mid-2026. The ORIC-944 program also involves combination studies with AR inhibitors like apalutamide and darolutamide.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Channels

The Channels block for ORIC Pharmaceuticals, Inc. centers on disseminating critical clinical progress and maintaining financial transparency with stakeholders while actively managing its global clinical footprint.

Global network of clinical trial sites in North America and Europe

ORIC Pharmaceuticals, Inc. utilizes a network of clinical trial sites to advance its lead candidates, ORIC-944 and enozertinib (ORIC-114). The company is currently enrolling studies across multiple indications, which necessitates a geographically distributed site network, primarily in North America and Europe, given the typical scope of US-headquartered biopharma trials.

• Currently enrolling Phase 1b study of ORIC-944 in prostate cancer with AR inhibitors.
• Currently enrolling Phase 1b/2 study of single-agent enozertinib in EGFR/HER2 mutated NSCLC.
• Currently enrolling Phase 1b study of enozertinib in combination with subcutaneous amivantamab in NSCLC with EGFR exon 20 mutations.

The operational focus is on advancing these programs, supported by $413.0M in cash, cash equivalents, and investments as of the third quarter of 2025. This financial position is projected to fund the operating plan into 2H 2028.

Investor Relations website for financial and pipeline updates

The primary digital channel for investor communication is the Investor Relations section of the corporate website, www.oricpharma.com. This channel delivers formal financial disclosures and pipeline milestones, such as the Q3 2025 financial results reported on November 13, 2025.

Here's a look at the recent financial and pipeline context delivered through this channel:

Metric/Update	Value/Date	Context
Cash, Cash Equivalents, and Investments (Q3 2025)	$413.0M	As of September 30, 2025
Projected Cash Runway	Into 2H 2028	Following strategic pipeline prioritization
Workforce Reduction	Approx. 20%	Streamlining operations to focus on lead programs
ORIC-944 Phase 3 Trial Initiation Target	1H 2026	For metastatic castration-resistant prostate cancer (mCRPC)
ORIC-114 Registrational Trial Initiation Target	2026	Focusing on first-line NSCLC settings

Scientific and medical conferences for data dissemination

Conferences serve as the crucial channel for disseminating primary clinical data to the scientific and medical community. ORIC Pharmaceuticals, Inc. actively presents at key industry events to build scientific credibility for its assets.

• Presented enozertinib (ORIC-114) data at the ESMO Asia Congress 2025 (December 5-7).
• Participated in the 8th Annual Evercore Healthcare Conference on November 24, 2025.
• Management participated in one-on-one meetings at the Guggenheim\'s 2nd Annual Healthcare Innovation Conference (November 11, 2025) and the Jefferies London Healthcare Conference (November 19, 2025).

The data presented at ESMO Asia 2025 included an Overall Response Rate (ORR) of 35% in the enozertinib 80 mg QD cohort for previously treated NSCLC patients with HER2 exon 20 mutations.

Future channel: Specialty pharmaceutical distributors upon commercialization

This channel is currently prospective, contingent upon successful progression through planned late-stage trials. The company is planning to initiate registrational trials for both lead programs in 2026. Upon potential regulatory approval, ORIC Pharmaceuticals, Inc. will need to establish relationships with specialty pharmaceutical distributors to manage the supply chain and market access for its targeted oncology therapies.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Customer Segments

The customer segments for ORIC Pharmaceuticals, Inc. (ORIC) are defined by the specific patient populations targeted by its clinical pipeline candidates, ORIC-944 and enozertinib (ORIC-114), as well as potential strategic partners.

Oncologists and hematologists treating advanced cancers are key decision-makers and prescribers. Their adoption is influenced by clinical trial results and the potential for best-in-class profiles. As of the third quarter ended September 30, 2025, ORIC Pharmaceuticals had a market capitalization of $1.2B, with a stock price of $12.38 as of November 5, 2025. The company reported cash, cash equivalents and investments totaling $327.7 million as of June 30, 2025. This financial position is expected to fund the operating plan into 2H 2028.

Patients with metastatic castration-resistant prostate cancer (mCRPC) are the target for ORIC-944, a PRC2 inhibitor being tested in combination with androgen receptor pathway inhibitors like apalutamide (ERLEADA) or darolutamide (NUBEQA). The global prostate cancer market is projected to reach $29.2 billion by 2035, with approximately 10% to 20% of all prostate cancers classified as castration-resistant.

Efficacy data from the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for mCRPC patients, with a cutoff date of September 22, 2025, demonstrates the potential value proposition for this segment:

Efficacy Endpoint (ORIC-944 Combination)	Response Rate	Confirmation Status
PSA50 Response Rate	55%	Confirmed in 40%
PSA90 Response Rate	20%	All confirmed

This data is based on patients previously treated with a median of three lines of prior therapy.

Patients with NSCLC having specific EGFR/HER2 exon 20 or atypical mutations are the focus for enozertinib (ORIC-114). The prevalence of these mutations defines the addressable patient pool:

• HER2 exon 20 insertion mutations: observed in approximately 1.5% of all NSCLC patients.
• Atypical EGFR mutations: observed in approximately 2.9% of all NSCLC patients.

For previously treated NSCLC patients with HER2 exon 20 mutations, data presented as of an August 29, 2025 cutoff showed activity:

Dose (Enozertinib QD)	Patients Dosed	Objective Response Rate (ORR)	Disease Control Rate (DCR)
80 mg	26	35% (26% confirmed)	100%
120 mg	23	Not explicitly stated as 35% for this group alone	Not explicitly stated as 100% for this group alone

Enrollment for the HER2 exon 20 mutation population is complete, with no further development planned in that specific group. The 80 mg QD dose was selected for potential Phase 3 development based on data across other EGFR exon 20 and atypical mutation populations. Approximately 47% of the HER2 exon 20 patients at baseline had brain metastases.

Large pharmaceutical companies for potential future licensing/M&A represent a segment for potential non-dilutive financing or commercialization partnerships. ORIC Pharmaceuticals established three strategic partnerships with major pharmaceutical companies as of February 2025. Following a strategic pipeline prioritization, the Company announced it will explore potential partnering of its preclinical programs.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Cost Structure

You're looking at the core burn rate for ORIC Pharmaceuticals, Inc. (ORIC) as of late 2025, and honestly, it's what you expect for a clinical-stage biotech: it's almost entirely driven by science.

The Cost Structure for ORIC Pharmaceuticals, Inc. (ORIC) is overwhelmingly dominated by Research & Development (R&D) expenses, which is the engine fueling their pipeline advancement. For the third quarter of 2025, the Total Operating Expenses were reported at \$36.671 million. This figure reflects the necessary investment to push ORIC-944 and enozertinib through their respective clinical stages.

Here's a quick look at how that total operating spend broke down for the quarter ended September 30, 2025:

Expense Category	Q3 2025 Amount (in millions USD)
Total Operating Expenses	\$36.671
Research & Development (R&D) Expenses	\$28.8
General and Administrative (G&A) Expenses	\$7.9

Digging into that R&D spend, you see where the money is actually going to the bench and the bedside. The R&D expenses for the quarter were \$28.8 million. A significant portion of that external spend was dedicated to the enozertinib program, with \$9.0M specifically attributed to external R&D costs for enozertinib in Q3 2025. The internal R&D costs, which include personnel and stock-based compensation, were \$10.3 million for the quarter, and ORIC-944 manufacturing costs were \$5.6 million externally, plus \$3.8 million for preclinical/other external costs. It's all about program advancement, so you need to track those external costs closely.

General and Administrative (G&A) expenses were \$7.9 million in Q3 2025, a slight increase from the prior year, reflecting higher personnel and services costs as the company streamlined operations. Furthermore, this quarter included a specific, non-recurring cost related to that streamlining effort: a one-time charge of \$1.9 million recognized for termination benefits following the workforce reduction. This kind of opex friction is common when a company narrows its focus to lead programs.

You can see the key cost drivers clearly:

• R&D expenses were \$28.8 million for the quarter.
• External costs for enozertinib totaled \$9.0 million.
• G&A was \$7.9 million.
• A one-time charge of \$1.9 million hit the books.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Revenue Streams

ORIC Pharmaceuticals, Inc. is currently operating in a pre-revenue phase, meaning product sales are not yet a source of income. For the quarter ended September 30, 2025, the reported Actual Revenue was N/A, which aligns with the reported net loss of $32.6 million for the last quarter.

The primary focus for future revenue generation is centered on the successful clinical progression and eventual commercialization of its two lead product candidates. The company is actively advancing these programs toward potential registrational studies, which is the critical step before generating sales revenue.

Future potential revenue streams are tied directly to these clinical assets:

• ORIC-944: An allosteric inhibitor of the polycomb repressive complex 2 (PRC2), being developed for prostate cancer.
• Enozertinib (ORIC-114): A brain-penetrant inhibitor targeting specific EGFR and HER2 mutations, being developed for multiple genetically defined cancers, including lung cancer.

ORIC Pharmaceuticals expects to report four clinical data readouts across both the ORIC-944 and enozertinib programs through mid-2026, with a potential initiation of registrational trials for both programs targeted in 2026. The World Health Organization has officially recognized 'enozertinib' as its generic name.

Potential milestone payments from strategic licensing or co-development deals represent another non-sales revenue component. While specific deal terms aren't public, the company's focus on advancing these programs to registrational studies suggests that achieving these key clinical milestones could trigger pre-agreed payments from any existing or future partners.

Interest income is derived from the significant balance of cash and investments held on the balance sheet. As of September 30, 2025, ORIC Pharmaceuticals reported cash, cash equivalents, and investments totaling approximately $413 million. This substantial balance is projected to fund the revised operating plan into the second half of 2028 (2H 2028) and beyond the anticipated primary endpoint readouts from the first Phase 3 trials.

Here's a quick look at the financial position supporting this runway:

Financial Metric	Amount (USD Millions)	Period End Date
Cash and Investments Balance	$413.0	September 30, 2025
Research & Development Expenses	$28.8	Three Months Ended September 30, 2025
Cash Runway Projection	Into 2H 2028	As of November 2025

The company has made a prudent decision to substantially reduce investment in discovery research to direct financial resources toward these lead clinical programs.